L&T Technology Services Unveils Cutting-Edge AI Experience Zone Built on NVIDIA AI
New Experience Zone in LTTS’ Bengaluru, India design hub will cater to clients in the Mobility and Tech segments
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global digital engineering and R&D services company, is proud to announce the grand opening of its state-of-the-art LTTS Experience Zone at its design hub in Bengaluru benefitting customers in segments like Mobility and Tech. This AI-driven LTTS Experience Zone, leveraging the NVIDIA AI platform, is set to serve clients in the Mobility and Tech segments.
The LTTS Experience Zone offers an immersive environment where visitors can engage with live demonstrations, interactive displays and expert consultations. It showcases the transformative power of NVIDIA AI, pushing the boundaries of AI-driven technologies to address complex challenges in critical sectors.
In healthcare, LTTS' Software Defined Architectures, powered by NVIDIA Holoscan andNVIDIA IGX, are set to transform healthcare delivery with AI-based diagnostics, real-time data analysis, and precision annotation, enhancing efficiency, accuracy, and broadening access to underserved regions.
The telecommunications sector stands to benefit from generative AI and NVIDIA AI solutions, which will bolster connectivity, network resilience, and 5G integration. LTTS is enhancing product engineering services by integrating 5G, network virtualization and master telco network solutions from design to deployment, thus improving communication across urban and rural landscapes.
For the Mobility segment, the collaboration between NVIDIA and LTTS will offer advanced solutions for safety, automation, and predictive maintenance, optimizing operations and enhancing passenger safety and experience.
With its focus on fostering dialogue and accelerating the adoption of next-gen solutions, LTTS is driving a future where technology is seamlessly integrated across industries. LTTS is upskilling over 1,000 engineers on NVIDIA software, including the NVIDIA AI Enterprise software platform. This investment in education and training will enable LTTS to accelerate AI adoption to solve complex challenges.
“We are excited to launch the LTTS Experience Zone, which underscores LTTS’ dedication to innovation and leadership in technology,” said Abhishek Sinha, Executive Director and President Medical, Smart World & Functions, L&T Technology Services. "In today’s fast-paced world, every customer seeks real-time AI solutions for critical areas such as surgery, shop floor operations, commuting experience, and connectivity. Our partnership with NVIDIA empowers us to deliver these cutting-edgesolutions. This centre will be a pivotal hub for collaboration and exploration, propelling advancements in the Tech and Mobility sectors that impact billions of lives globally.”
“Embracing generative AI is essential for unlocking the next wave of innovation, with India poised to establish technological sovereignty with homegrown solutions. The launch of LTTS' AI Experience Zone, leveraging the NVIDIA AI platform, creates an immersive space for exploring transformative, AI applications across industries,” said Vishal Dhupar, Managing Director, Asia South, NVIDIA.
The LTTS Experience Zone will be open to industry experts, partners, and customers for guided tours, demonstrations, and discussions. Appointments can be booked through LTTS.
About L&T Technology Services Ltd
L&T Technology Services (LTTS) is a global leader in engineering and technology services. A listed subsidiary of Larsen & Toubro (L&T), we offer design, development, testing, and sustenance services across products and processes.
Purposeful. Agile. Innovation. is how we drive growth across the Mobility, Sustainability, and Tech segments. Our customer base includes 69 Fortune 500 companies and 57 top ER&D companies across industrial products, medical devices, transportation, telecom & hi-tech, and process industries. Headquartered in India, we have over 23,700 employees across 22 global design centers, 30 global sales offices, and 108 innovation labs, as of September 30, 2024.
For additional information about L&T Technology Services log on to www.LTTS.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241023001102/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release
Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release
Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release
–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release
Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom